Repeated administration of α-hederin results in alterations in maternal zinc status and adverse developmental outcome in the rat

Jodie Y. Duffy, Donald Baines, Gary J. Overmann, Carl L Keen, George P. Daston

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The administration of α-hederin, an inducer of metallothionein, results in a secondary zinc deficiency that may be an important maternally mediated mechanism of developmental toxicity. Previous studies have shown adverse developmental outcome with a single administration of α-hederin to rats on gestation day (GD) 8 or 11. The objective of this study was to determine whether dosing of α-hederin throughout organogenesis would result in a sustained elevation of maternal hepatic metallothionein and subsequent developmental abnormalities. Rats were administered dosage levels of 0 (vehicle only), 20, or 30 μmol/kg from GD 6-15. Maternal hepatic metallothionein levels were 10-fold higher on GD 16 in the treatment groups than the controls. Consequently, liver zinc concentrations increased 60% and 54%, whereas plasma levels decreased 23% and 33% in the 20 and 30 μmol/kg treatment groups, respectively. At GD 20, mean fetal weights of the treatment litters were 11% less than control litters. The administration of α-hederin resulted in a threefold increase in the number of offspring that exhibited developmental abnormalities, including visceral and skeletal malformations. Following an oral pulse of 65Zn subsequent to treatment with 0 or 20 μmol/kg of α-hederin, the distribution of 65Zn to the liver of treated dams was twice that of controls, whereas the radiolabeled zinc apportioned to the decidua and uterus decreased by 44%. Furthermore, the 65Zn detected in the embryos from treated dams was 70% lower than in embryos from control dams. In conclusion, low doses of a metallothionein inducer administered to the dam from GD 6-15 resulted in a sustained elevation of hepatic metallothionein and a subsequent redistribution of zinc leading to a decrease in the zinc available to the embryo and ultimately to adverse development of the offspring. Repeated dosing throughout organogenesis, as required in regulated safety assessment testing, increased the severity of the effects previously observed with single large dosages of the toxicant administered during midgestation.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalTeratology
Volume56
Issue number5
DOIs
StatePublished - Nov 1997

Fingerprint

Oleanolic Acid
Metallothionein
Zinc
Rats
Dams
Mothers
Pregnancy
Liver
Embryonic Structures
Organogenesis
Decidua
Fetal Weight
Uterus
Toxicity
Plasmas
Safety
Control Groups
Testing

ASJC Scopus subject areas

  • Developmental Biology
  • Embryology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Repeated administration of α-hederin results in alterations in maternal zinc status and adverse developmental outcome in the rat. / Duffy, Jodie Y.; Baines, Donald; Overmann, Gary J.; Keen, Carl L; Daston, George P.

In: Teratology, Vol. 56, No. 5, 11.1997, p. 327-334.

Research output: Contribution to journalArticle

Duffy, Jodie Y. ; Baines, Donald ; Overmann, Gary J. ; Keen, Carl L ; Daston, George P. / Repeated administration of α-hederin results in alterations in maternal zinc status and adverse developmental outcome in the rat. In: Teratology. 1997 ; Vol. 56, No. 5. pp. 327-334.
@article{210ae9482f3c401eb8c189e4c34ab7f8,
title = "Repeated administration of α-hederin results in alterations in maternal zinc status and adverse developmental outcome in the rat",
abstract = "The administration of α-hederin, an inducer of metallothionein, results in a secondary zinc deficiency that may be an important maternally mediated mechanism of developmental toxicity. Previous studies have shown adverse developmental outcome with a single administration of α-hederin to rats on gestation day (GD) 8 or 11. The objective of this study was to determine whether dosing of α-hederin throughout organogenesis would result in a sustained elevation of maternal hepatic metallothionein and subsequent developmental abnormalities. Rats were administered dosage levels of 0 (vehicle only), 20, or 30 μmol/kg from GD 6-15. Maternal hepatic metallothionein levels were 10-fold higher on GD 16 in the treatment groups than the controls. Consequently, liver zinc concentrations increased 60{\%} and 54{\%}, whereas plasma levels decreased 23{\%} and 33{\%} in the 20 and 30 μmol/kg treatment groups, respectively. At GD 20, mean fetal weights of the treatment litters were 11{\%} less than control litters. The administration of α-hederin resulted in a threefold increase in the number of offspring that exhibited developmental abnormalities, including visceral and skeletal malformations. Following an oral pulse of 65Zn subsequent to treatment with 0 or 20 μmol/kg of α-hederin, the distribution of 65Zn to the liver of treated dams was twice that of controls, whereas the radiolabeled zinc apportioned to the decidua and uterus decreased by 44{\%}. Furthermore, the 65Zn detected in the embryos from treated dams was 70{\%} lower than in embryos from control dams. In conclusion, low doses of a metallothionein inducer administered to the dam from GD 6-15 resulted in a sustained elevation of hepatic metallothionein and a subsequent redistribution of zinc leading to a decrease in the zinc available to the embryo and ultimately to adverse development of the offspring. Repeated dosing throughout organogenesis, as required in regulated safety assessment testing, increased the severity of the effects previously observed with single large dosages of the toxicant administered during midgestation.",
author = "Duffy, {Jodie Y.} and Donald Baines and Overmann, {Gary J.} and Keen, {Carl L} and Daston, {George P.}",
year = "1997",
month = "11",
doi = "10.1002/(SICI)1096-9926(199711)56:5<327::AID-TERA6>3.0.CO;2-U",
language = "English (US)",
volume = "56",
pages = "327--334",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Repeated administration of α-hederin results in alterations in maternal zinc status and adverse developmental outcome in the rat

AU - Duffy, Jodie Y.

AU - Baines, Donald

AU - Overmann, Gary J.

AU - Keen, Carl L

AU - Daston, George P.

PY - 1997/11

Y1 - 1997/11

N2 - The administration of α-hederin, an inducer of metallothionein, results in a secondary zinc deficiency that may be an important maternally mediated mechanism of developmental toxicity. Previous studies have shown adverse developmental outcome with a single administration of α-hederin to rats on gestation day (GD) 8 or 11. The objective of this study was to determine whether dosing of α-hederin throughout organogenesis would result in a sustained elevation of maternal hepatic metallothionein and subsequent developmental abnormalities. Rats were administered dosage levels of 0 (vehicle only), 20, or 30 μmol/kg from GD 6-15. Maternal hepatic metallothionein levels were 10-fold higher on GD 16 in the treatment groups than the controls. Consequently, liver zinc concentrations increased 60% and 54%, whereas plasma levels decreased 23% and 33% in the 20 and 30 μmol/kg treatment groups, respectively. At GD 20, mean fetal weights of the treatment litters were 11% less than control litters. The administration of α-hederin resulted in a threefold increase in the number of offspring that exhibited developmental abnormalities, including visceral and skeletal malformations. Following an oral pulse of 65Zn subsequent to treatment with 0 or 20 μmol/kg of α-hederin, the distribution of 65Zn to the liver of treated dams was twice that of controls, whereas the radiolabeled zinc apportioned to the decidua and uterus decreased by 44%. Furthermore, the 65Zn detected in the embryos from treated dams was 70% lower than in embryos from control dams. In conclusion, low doses of a metallothionein inducer administered to the dam from GD 6-15 resulted in a sustained elevation of hepatic metallothionein and a subsequent redistribution of zinc leading to a decrease in the zinc available to the embryo and ultimately to adverse development of the offspring. Repeated dosing throughout organogenesis, as required in regulated safety assessment testing, increased the severity of the effects previously observed with single large dosages of the toxicant administered during midgestation.

AB - The administration of α-hederin, an inducer of metallothionein, results in a secondary zinc deficiency that may be an important maternally mediated mechanism of developmental toxicity. Previous studies have shown adverse developmental outcome with a single administration of α-hederin to rats on gestation day (GD) 8 or 11. The objective of this study was to determine whether dosing of α-hederin throughout organogenesis would result in a sustained elevation of maternal hepatic metallothionein and subsequent developmental abnormalities. Rats were administered dosage levels of 0 (vehicle only), 20, or 30 μmol/kg from GD 6-15. Maternal hepatic metallothionein levels were 10-fold higher on GD 16 in the treatment groups than the controls. Consequently, liver zinc concentrations increased 60% and 54%, whereas plasma levels decreased 23% and 33% in the 20 and 30 μmol/kg treatment groups, respectively. At GD 20, mean fetal weights of the treatment litters were 11% less than control litters. The administration of α-hederin resulted in a threefold increase in the number of offspring that exhibited developmental abnormalities, including visceral and skeletal malformations. Following an oral pulse of 65Zn subsequent to treatment with 0 or 20 μmol/kg of α-hederin, the distribution of 65Zn to the liver of treated dams was twice that of controls, whereas the radiolabeled zinc apportioned to the decidua and uterus decreased by 44%. Furthermore, the 65Zn detected in the embryos from treated dams was 70% lower than in embryos from control dams. In conclusion, low doses of a metallothionein inducer administered to the dam from GD 6-15 resulted in a sustained elevation of hepatic metallothionein and a subsequent redistribution of zinc leading to a decrease in the zinc available to the embryo and ultimately to adverse development of the offspring. Repeated dosing throughout organogenesis, as required in regulated safety assessment testing, increased the severity of the effects previously observed with single large dosages of the toxicant administered during midgestation.

UR - http://www.scopus.com/inward/record.url?scp=0031441019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031441019&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9926(199711)56:5<327::AID-TERA6>3.0.CO;2-U

DO - 10.1002/(SICI)1096-9926(199711)56:5<327::AID-TERA6>3.0.CO;2-U

M3 - Article

VL - 56

SP - 327

EP - 334

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 5

ER -